An in vitro cynomolgus vascular surrogate system for preclinical drug assessment and human translation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 10, 2015, Pages 2185-2195

  Cole, Banumathi K ^a,d   Simmers, Michael B ^a,d   Feaver, Ryan ^d   Qualls, Charles W ^e   Sol Collado, M ^a,d   Berzin, Erica ^a,d   Figler, Robert A ^a,d   Pryor, Andrew W ^b,d   Lawson, Mark ^a,d   Mackey, Aaron ^a,d   Manka, David ^a,d   Wamhoff, Brian R ^c,d   Turk, James R ^e   Blackman, Brett R ^c,d  

^a VP Research and Development Fiber Innovation Technology   (United States)

^b Pathology   (United States)

^c HemoShear Therapeutics   (United States)

^d Amgen   (United States)

^e AMGEN INC   (United States)

Author keywords

Cell cycle; Hemodynamics; Hydroxymethylglutaryl CoA reductase inhibitors; Inflammation; Macaca fascicularis

Indexed keywords

ALPHA ACTININ 2; ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 2; ATORVASTATIN; CERIVASTATIN; CHEMOKINE RECEPTOR CCR4; CXCL2 CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 4; MANGANESE SUPEROXIDE DISMUTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STROMAL CELL DERIVED FACTOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ADHESION PROTEIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING; BLOOD FLOW VELOCITY; BLOOD VESSEL WALL; CARDIOVASCULAR SYSTEM; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; GENE EXPRESSION; HEMODYNAMICS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MACACA FASCICULARIS; MAXIMUM DRUG EFFECT; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PULSATILE FLOW; RNA SEQUENCE; SHEAR STRESS; SMOOTH MUSCLE FIBER; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BLOOD; CARDIOVASCULAR DISEASES; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM; PROCEDURES; SPECIES DIFFERENCE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO TECHNIQUES; LIPOPROTEINS, LDL; MACACA FASCICULARIS; MODELS, CARDIOVASCULAR; MUSCLE, SMOOTH, VASCULAR; SPECIES SPECIFICITY;

EID: 84942247427     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306245     Document Type: Article

References (46)

1. Hastings NE, Simmers MB, McDonald OG, Wamhoff BR, Blackman BR. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol. 2007;293:C1824-C1833. doi: 10. 1152/ ajpcell. 00385. 2007.
2. Blackman BR, García-Cardeña G, Gimbrone MA Jr. A new in vitro model to evaluate differential responses of endothelial cells to simulated arterial shear stress waveforms. J Biomech Eng. 2002;124:397-407.
3. Feaver RE, Gelfand BD, Blackman BR. Human haemodynamic frequency harmonics regulate the inflammatory phenotype of vascular endothelial cells. Nat Commun. 2013;4:1525. doi: 10. 1038/ncomms2530.
4. Gelfand BD, Epstein FH, Blackman BR. Spatial and spectral heterogeneity of time-varying shear stress profiles in the carotid bifurcation by phasecontrast MRI. J Magn Reson Imaging. 2006;24:1386-1392. doi: 10. 1002/ jmri. 20765.
5. Orr AW, Stockton R, Simmers MB, Sanders JM, Sarembock IJ, Blackman BR, Schwartz MA. Matrix-specific p21-activated kinase activation regulates vascular permeability in atherogenesis. J Cell Biol. 2007;176:719-727. doi: 10. 1083/jcb. 200609008.
6. Simmers MB, Pryor AW, Blackman BR. Arterial shear stress regulates endothelial cell-directed migration, polarity, and morphology in confluent monolayers. Am J Physiol Heart Circ Physiol. 2007;293:H1937-H1946. doi: 10. 1152/ajpheart. 00534. 2007.
7. Weingand KW. Atherosclerosis research in cynomolgus monkeys (Macaca fascicularis). Exp Mol Pathol. 1989;50:1-15.
8. Cefalu WT, Wagner JD. Aging and atherosclerosis in human and nonhuman primates. Age (Omaha). 1997;20:15-28. doi: 10. 1007/ s11357-997-0002-4.
9. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem. 2007;282:13769-13779. doi: 10. 1074/ jbc. M700078200.
10. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone MA Jr, García-Cardeña G, Jain MK. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199:1305-1315. doi: 10. 1084/jem. 20031132.
11. Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. 2010;47:168-180. doi: 10. 1159/000250095.
12. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006:83:456S-460S.
13. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801. doi: 10. 1152/physrev. 00041. 2003.
14. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD, Vasiliou V. Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev. 2012;64:520-539. doi: 10. 1124/pr. 111. 005538.
15. Chu TJ, Peters DG. Serial analysis of the vascular endothelial transcriptome under static and shear stress conditions. Physiol Genomics. 2008;34:185-192. doi: 10. 1152/physiolgenomics. 90201. 2008.
16. Davis ME, Grumbach IM, Fukai T, Cutchins A, Harrison DG. Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding. J Biol Chem. 2004;279:163-168. doi: 10. 1074/jbc. M307528200.
17. Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, Pannekoek H, Horrevoets AJ. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood. 2002;100:1689-1698. doi: 10. 1182/ blood-2002-01-0046.
18. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A. 1993;90:5999-6003.
19. Melchionna R, Porcelli D, Mangoni A, Carlini D, Liuzzo G, Spinetti G, Antonini A, Capogrossi MC, Napolitano M. Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis. FASEB J. 2005;19:629-631. doi: 10. 1096/ fj. 04-2219fje.
20. Tressel SL, Huang RP, Tomsen N, Jo H. Laminar shear inhibits tubule formation and migration of endothelial cells by an angiopoietin-2 dependent mechanism. Arterioscler Thromb Vasc Biol. 2007;27:2150-2156. doi: 10. 1161/ATVBAHA. 107. 150920.
21. Marzetta CA, Rudel LL. A species comparison of low density lipoprotein heterogeneity in nonhuman primates fed atherogenic diets. J Lipid Res. 1986;27:753-762.
22. Stucchi AF, Nicolosi RJ, Karge WH 3rd, Ausman LM, Ordovas JM. Dietary cholesterol affects serum lipids, lipoproteins and LDL metabolism in cynomolgus monkeys in a dose-dependent manner. J Nutr. 1998;128:1104-1113.
23. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130:1793-1806. doi: 10. 1053/j. gastro. 2006. 02. 034.
24. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos. 2006;34:738-742. doi: 10. 1124/dmd. 105. 007534.
25. Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/ kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340:228-236. doi: 10. 1124/jpet. 111. 187419.
26. Camnitz W, Burdick MD, Strieter RM, Mehrad B, Keeley EC. Dosedependent effect of statin therapy on circulating CXCL12 levels in patients with hyperlipidemia. Clin Transl Med. 2012;1:23. doi: 10. 1186/2001-1326-1-23.
27. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194-1199.
28. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 2003;24:225-248.
29. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22:165-170. doi: 10. 1097/ MOL. 0b013e3283453e41.
30. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684-691.
31. Jilma B, Joukhadar C, Derhaschnig U, Rassoul F, Richter V, Wolzt M, Dorner GT, Petternel V, Wagner OF. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia. Clin Sci (Lond). 2003;104:189-193. doi: 10. 1042/CS20020168.
32. Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond). 2004;106:215-217. doi: 10. 1042/ CS20030291.
33. Feng Y, Cai ZR, Tang Y, Hu G, Lu J, He D, Wang S. TLR4/NF-?B signaling pathway-mediated and oxLDL-induced up-regulation of LOX-1, MCP-1, and VCAM-1 expressions in human umbilical vein endothelial cells. Genet Mol Res. 2014;13:680-695. doi: 10. 4238/2014. January. 28. 13.
34. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest. 1995;95:1262-1270. doi: 10. 1172/JCI117776.
35. Kang S, Woo HH, Kim K, Lim KM, Noh JY, Lee MY, Bae YM, Bae ON, Chung JH. Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin. Toxicol Sci. 2014;138:446-556. doi: 10. 1093/toxsci/ kfu011.
36. Li J, Jiang J, Yin H, Wang L, Tian R, Li H, Wang Z, Li D, Wang Y, Gui Y, Walsh MP, Zheng XL. Atorvastatin inhibits myocardin expression in vascular smooth muscle cells. Hypertension. 2012;60:145-153. doi: 10. 1161/ HYPERTENSIONAHA. 112. 195644.
37. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;11:306-315. doi: 10. 1634/ theoncologist. 11-3-306.
38. Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation. 2012;126:e282-e284. doi: 10. 1161/ CIRCULATIONAHA. 112. 122135.
39. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's doubleedged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25:4777-4786. doi: 10. 1038/ sj. onc. 1209603.
40. Niinaka Y, Harada K, Fujimuro M, Oda M, Haga A, Hosoki M, Uzawa N, Arai N, Yamaguchi S, Yamashiro M, Raz A. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res. 2010;70:9483-9493. doi: 10. 1158/0008-5472. CAN-09-3880.
41. Tsutsumi S, Yanagawa T, Shimura T, Fukumori T, Hogan V, Kuwano H, Raz A. Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem. 2003;278:32165-32172. doi: 10. 1074/jbc. M304537200.
42. Preedy VR, Crabb DW, Farrés J, Emery PW. Alcoholic myopathy and acetaldehyde. Novartis Found Symp. 2007;285:158-77; discussion 177.
43. Pappa A, Brown D, Koutalos Y, DeGregori J, White C, Vasiliou V. Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005;280:27998-28006. doi: 10. 1074/jbc. M503698200.
44. Simmers M, Cole B, Mackey A, Manka D, Blackman BR, Wamhoff BR. Altered hemodynamics play a critical role in fenoldopam-induced mesenteric vasculitis in the rat. 2014 Annual Meeting Abstract Supplement, Society of Toxicology, 2014. Abstract no. 1129a.
45. Dalmas DA, Scicchitano MS, Mullins D, Hughes-Earle A, Tatsuoka K, Magid-Slav M, Frazier KS, Thomas HC. Potential candidate genomic biomarkers of drug induced vascular injury in the rat. Toxicol Appl Pharmacol. 2011;257:284-300. doi: 10. 1016/j. Taap. 2011. 09. 015.
46. Dalmas DA, Scicchitano MS, Chen Y, Kane J, Mirabile R, Schwartz LW, Thomas HC, Boyce RW. Transcriptional profiling of laser capture microdissected rat arterial elements: fenoldopam-induced vascular toxicity as a model system. Toxicol Pathol. 2008;36:496-519. doi: 10. 1177/0192623307311400.